Axion’s Maestro platform elevates MEA technology to the high-throughput arena, enabling analysis of neural and cardiac networks on an unprecedented scale. This system is ideal for large-scale cellular analysis in secondary screening applications. The plug-n-play Maestro system comes with Axion’s Integrated Studio (AxIS) software, making MEA experiments simpler and faster than ever before.Request a Quote
The Axion Muse introduces fully integrated stimulation and recording to MEA platforms while dramatically reducing the cost and complexity of MEA research. This efficient, flexible, and compact system is well suited for virtually any laboratory environment. When coupled with Maestro, Muse provides an excellent way to qualify an assay before scaling up to the high-throughput Maestro system.Request a Quote
Axion’s multiwell plates allow scientists to conduct 12, 48, and soon 96 simultaneous experiments in an industry-standard microtiter format. By dramatically improving productivity, Axion has made MEA technology practical for applications requiring high-throughput capability such as toxicology, drug screening, and safety pharmacology.
Single-well MEAs are ideally suited for the electrophysiological investigation of both neural and cardiac cultures. Individual microelectrodes are capable of simultaneously monitoring the activity of a dozen or more cells; the arrangement of multiple electrodes into a grid extends the recording range across a 2×2 mm area, providing concurrent access to both single-cell and network-level activity.
Axion’s MEA systems can replicate a brainwave or a heartbeat in a dish. As a result, toxicity and efficacy can be assessed earlier in the drug development process, and with greater sensitivity and accuracy. These comprehensive system-level evaluations provide an in vitro solution to reducing animal testing, a key objective of the Tox21 and REACH initiatives.
Axion’s MEA systems provide a label-free in vitro platform for direct measurement of electrical activity in neurons and cardiomyocytes, while the efficiency and convenience of Axion’s standard MEA plates facilitate use for screening-level applications. The large number of electrodes per well reveals detailed information about systems-level signal propogation.
Axion will be featured on two posters at this year’s annual meeting. Visit us at either one to learn more about our applications. Monday Morning, March 11 9:30 AM to 12:30 PM Exhibit Hall C–D Displayed: 9:30 AM–12:30 PM Author Attended: 9:30 AM–11:00 AM Abstract #89 Poster Board #123 Development of an In Vitro Multiwell [...]
More NewsCyprotex PLC (AIM:CRX), the specialist preclinical contract research organization (CRO), today announces the launch of eCiphrCardio, an assay to assess potential cardiotoxicity of compounds in early drug development. This assay is based on microelectrode array (MEA) technology using Axion’s Maestro Multiwell MEA platform. Visit Source
More News